BOSTON — PepGen Inc., a clinical-stage biotechnology company developing next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases, announced the appointment of Joseph Vittiglio, Esq., as chief business and legal officer. The company said he brings more than 20 years of executive experience in legal strategy, compliance, corporate development, and governance across multiple publicly traded biotech organizations.
“Joe is a deeply experienced legal and business leader with a proven track record guiding companies through complex transactions, regulatory milestones, financings, product launches, and strategic partnerships,” said James McArthur, PhD, president and chief executive officer of PepGen. “We are excited to welcome him to PepGen’s executive leadership team as we continue to make significant progress advancing our PGN-EDODM1 program and prepare for the anticipated 2026 readouts from the 5 mg/kg and 10 mg/kg cohorts in our FREEDOM2-EDODM1 study in DM1 patients.”
Vittiglio previously provided consulting support to PepGen throughout 2025. Before that, he served as chief business and legal officer and corporate secretary at bluebird bio, where he led global legal, compliance, and business development functions; supported the U.S. approval and launch of three gene therapy products; and helped drive more than $400 million in financings.
Prior to his tenure at bluebird, he was chief business and legal officer at Finch Therapeutics, where he guided the company’s IPO, built its public-company governance and compliance infrastructure, and oversaw an international intellectual property portfolio comprising more than 50 patent families. Earlier roles included chief business officer and general counsel at AMAG Pharmaceuticals and senior legal positions at Flexion Therapeutics, AVEO Pharmaceuticals and Oscient Pharmaceuticals. He began his legal career at Mintz.
Vittiglio earned a J.D. from Northeastern University School of Law and a B.A. in international relations from Tufts University.
